Affinity Asset Advisors LLC Has $4.15 Million Position in Perspective Therapeutics, Inc. (NYSE:CATX)

Affinity Asset Advisors LLC increased its holdings in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 160.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,300,000 shares of the company's stock after purchasing an additional 800,000 shares during the period. Affinity Asset Advisors LLC owned 1.92% of Perspective Therapeutics worth $4,147,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd purchased a new stake in Perspective Therapeutics in the fourth quarter valued at approximately $33,000. Aigen Investment Management LP purchased a new stake in Perspective Therapeutics during the fourth quarter valued at about $34,000. National Bank of Canada FI raised its holdings in shares of Perspective Therapeutics by 549,900.0% in the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock worth $35,000 after purchasing an additional 10,998 shares during the period. Vontobel Holding Ltd. acquired a new position in shares of Perspective Therapeutics in the 4th quarter valued at about $51,000. Finally, Trueblood Wealth Management LLC increased its position in Perspective Therapeutics by 37.0% during the 4th quarter. Trueblood Wealth Management LLC now owns 22,236 shares of the company's stock worth $71,000 after purchasing an additional 6,000 shares in the last quarter. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CATX has been the subject of several recent research reports. HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a research report on Monday, March 31st. Cantor Fitzgerald upgraded Perspective Therapeutics to a "strong-buy" rating in a research note on Tuesday, March 4th. Wedbush restated an "outperform" rating and issued a $11.00 price target on shares of Perspective Therapeutics in a report on Wednesday, March 26th. Scotiabank assumed coverage on shares of Perspective Therapeutics in a research note on Friday, March 7th. They set a "sector outperform" rating and a $15.00 price objective on the stock. Finally, Brookline Capital Management raised shares of Perspective Therapeutics to a "strong-buy" rating in a report on Monday, March 10th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $12.75.

Insider Buying and Selling

In other Perspective Therapeutics news, CFO Juan Graham bought 33,333 shares of the business's stock in a transaction that occurred on Friday, March 28th. The stock was acquired at an average cost of $2.25 per share, with a total value of $74,999.25. Following the completion of the purchase, the chief financial officer now directly owns 35,354 shares in the company, valued at approximately $79,546.50. This trade represents a 1,649.33 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, Director Robert F. Williamson III purchased 38,145 shares of the company's stock in a transaction on Monday, March 31st. The stock was bought at an average cost of $2.14 per share, for a total transaction of $81,630.30. Following the acquisition, the director now directly owns 108,982 shares of the company's stock, valued at $233,221.48. This represents a 53.85 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 115,696 shares of company stock valued at $256,344 in the last quarter. Company insiders own 3.52% of the company's stock.

Perspective Therapeutics Stock Performance

CATX stock traded up $0.09 during midday trading on Friday, reaching $1.94. The company had a trading volume of 806,996 shares, compared to its average volume of 1,023,760. The stock has a 50 day moving average price of $2.39 and a 200 day moving average price of $5.05. Perspective Therapeutics, Inc. has a fifty-two week low of $1.60 and a fifty-two week high of $19.05.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.